tradingkey.logo

IBio Initiates Non-Human Primate Study Of First-In-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention In Weight Regain After GLP-1 Treatment

ReutersJun 16, 2025 11:45 AM

- iBio Inc IBIO.O:

  • IBIO INITIATES NON-HUMAN PRIMATE STUDY OF FIRST-IN-CLASS ACTIVIN E ANTIBODY FOLLOWING POSITIVE PRECLINICAL DATA DEMONSTRATING PREVENTION IN WEIGHT REGAIN AFTER GLP-1 TREATMENT

  • IBIO INC - IBIO-610 DRIVES 8.9% BODY WEIGHT LOSS IN MICE

  • IBIO INC - PRECLINICAL RESULTS SHOW 26% FAT REDUCTION WITH IBIO-610

  • IBIO INC - IBIO-610 PREVENTS WEIGHT REGAIN IN MICE AFTER GLP-1 THERAPY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI